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IL-1 has served as a ground breaking molecule in immunology and
it is now experiencing a renaissance. Originally the description of
a cytokine acting at vanishingly low concentration on cells and
organs as diverse as the hypothalamus (fever) and T cells (1) was
without precedent in biology and paved the way to the whole field
of cytokines and their pleiotropic mode of action.
The discovery of the importance of IL-1 in defense against bac-
teria and of the Toll-IL-1 resistance (TIR, as originally defined)
domain was upstream of the discovery of Toll-like receptors (2).
Along the same line, the identification of MyD88 as the key adaptor
in the IL-1 receptor signaling cascade (3) prompted its identifica-
tion in Toll/TLR4 signaling (4, 5). The type II IL-1 receptor was
identified as a decoy for IL-1, thus providing a new paradigm in
receptor biology (6), subsequently extended to other cytokines
and growth factors (7). Stunning from this strong roots, IL-1 has
in recent years seen a renaissance. New relatives of IL-1 and IL-
1R have been identified and their function has been defined in
innate and adaptive immune responses. IL-1 family members have
emerged as key players in the differentiation of the main T helper
subsets, Th1, Th2, and Th17. Finally, anti-IL-1 strategies have had
a tremendous impact in autoinflammatory diseases and are being
tested in a variety of clinical conditions.
This volume brings together eight articles that are intended
to provide a summary about IL-1 family ligand and receptors
in inflammation and immunity. The eight articles are briefly
described below.
van de Veerdonk et al. focus their review on the IL-1 fam-
ily of ligands, describe their biological functions and provide new
insights in their biology (8). In particular they focus on the new IL-
1 family members, IL-37 and the cytokines belonging to the IL-36
subfamily and on the potency of blocking IL-1 in disease. Among
the ligands, a special focus on the biology of IL-18 as well as its role
in human disease is provided by the review by Dinarello et al. (9).
IL-18 is synthesized as an inactive precursor requiring process-
ing by caspase-1 into an active cytokine, similarly to IL-1β, and is
constitutively present in nearly all cell types. The activity of IL-18
is balanced by the presence of a high affinity naturally occurring
IL-18 binding protein (IL-18BP), which is now in clinical trials.
Most members of the IL-1 family, including the master pro-
inflammatory cytokine IL-1β, are leaderless proteins and are
released from the cell though a “non-classical” pathway of secre-
tion. Rubartelli et al. review current hypotheses on the mecha-
nisms of externalization of IL-1 family members and discuss their
relevance with respect to the different functions, as cytokines or as
DAMPs, played by IL-1 family members (10).
Members of IL-1R like receptor family include signaling mole-
cules and negative regulators. In our review, we present the latter,
which include the prototypic decoy receptor type 2 IL-1R and
“receptors” with regulatory function, such as TIR8/SIGIRR (11).
We suggest that the presence of multiple pathways of negative reg-
ulation of members of the IL-1/IL-1R family emphasizes the need
for a tight control of members of this fundamental system, which
mediates potentially devastating local and systemic inflammatory
reactions.
Voronov et al. present the role of IL-1 as a pleiotropic cytokine
in the context of cancer (12). In their secreted form, IL-1α and IL-
1β are involved in tumorigenesis and tumor invasiveness, whereas
IL-1α, when expressed on the cell membrane, stimulates anti-
tumor cell immunity. Differential patterns of IL-1α and IL-1β
expression and function have been observed in different tumors,
thus the authors suggest that better understanding of the role of
IL-1α and IL-1β in distinct malignancies will enable the applica-
tion of novel IL-1 modulation approaches in cancer patients as an
adjunct to conventional approaches.
Lopetuso et al. discuss the dichotomous functions of IL-
1 family members, such as IL-1, IL-1Ra, IL-18, and IL-33, in
gastrointestinal-related inflammatory disorders, depending on the
phase of disease or homeostasis and show that IL-37 is emerg-
ing as a potent anti-inflammatory cytokine which downregu-
lates colitis (13). In addition, they present data on IL-1 family
members suggesting novel pathogenic hypotheses and transla-
tional implications for inflammatory bowel disease (IBD) and
inflammation-associated colorectal cancer.
The review by Federici et al. presents inherited autoinflam-
matory diseases secondary to mutations of proteins of the
intracellular pathways deputed to the activation and secre-
tion of IL-1β (14). The authors show that the understand-
ing of the molecular pathways involved in these disorders has
clarified that similar pathogenic mechanisms play also a cru-
cial role in sustaining inflammation in several multi-factorial
inflammatory disorders and opened new perspectives for the
treatment of these autoinflammatory disorders based on IL-1
blockers.
Finally, Santarlasci et al. discuss the involvement of IL-1α and
IL-1β in the differentiation, activation, and maintenance or sur-
vival of the different Th cell subsets (15). Indeed, the differential
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expression of IL-1R1 on human CD4+ T cell subsets confers dis-
tinct capacities to acquire specific effector functions. In particular,
IL-1β is a key cytokine in Th17 development, acting through IL-
1R1 expressed already by the naïve CD4+ Th17 precursor, and
interestingly by a sub-set of Th1 cells possibly derived by plasticity
of Th17 cells.
The reviews collected in this issue of Frontiers will hopefully
provide the reader with the sense of diversity and impact of IL-1
family members in the activation and regulation of innate and
adaptive immune responses and in immunopathology.
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